LONDON, June 21 (Reuters) - Shire Plc said on Thursday the U.S. Food and Drug Administration (FDA) intended to approve Intuniv, its extended-release, non-stimulant treatment for attention deficit ...
LONDON, July 28 (Reuters) - U.S. regulators have delayed approval of Shire's new extended-release hyperactivity drug Intuniv but the British company still expects it to be launched in the United ...
Attention deficit hyperactivity disorder, or ADHD, is a common neurodevelopmental disorder that can affect children and adults. It’s often diagnosed during childhood or adolescence — in fact, an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results